An Open, Phase I, Dose Escalation and Dose Expansion Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Preliminary Efficacy of DR30303 in Patients With Advanced Solid Tumors
试验速览
- 阶段
- 1 期
- 状态
- 终止
- 发起方
- 入组人数
- 13
- 试验地点
- 1
- 主要终点
- Part 1：Incidence of dose limiting toxicities (DLTs)
研究概览
简要总结
This study is an open-label Phase 1, First in Human trial of DR30303, a recombinant humanized monoclonal antibody that targets Claudin18.2 (CLDN18.2). It is composed of humanized variable domain of heavy chain of antibody (VHH) fused with engineered immunoglobulin gamma-1(IgG1) Fc. It is being testing against advanced and/or metastatic solid tumors.
详细描述
This study is an open, phase I study to evaluate the safety, tolerability, pharmacokinetics and preliminary efficacy of DR30303 in patients with advanced solid tumors. The study is composed of two parts: part 1 is Dose escalation stage and part 2 is Dose expansion stage.
研究设计
- 研究类型
- Interventional
- 分配方式
- Na
- 干预模型
- Single Group
- 主要目的
- Treatment
- 盲法
- None
入排标准
- 年龄范围
- 18 Years 至 75 Years（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Fully informed of this study and voluntarily sign informed consent form (ICF).
- •Aged 18 to 75 years, gender is not limited.
- •Part 1: Dose escalation stage - the subject have histologically or cytologically confirmed locally advanced or metastatic malignant solid tumors who have failed or are intolerant to prior systemic therapy.
- •Part 2: Dose expansion stage- CLDN18.2 positive confirmed by central laboratory locally advanced unresectable or metastatic gastric cancer (GC)/gastroesophageal junction (GEJ ) or Pancreatic cancer those who had failed or were intolerant to at least 1 line of systemic therapy.
- •The Eastern Cooperative Oncology Group (ECOG) score is 0 to
- •Expected survival ≥ 3 months.
- •Adequate organ function.
- •Referring to the RECIST 1.1 standard, there is at least one measurable lesion.
排除标准
- •Radical radiotherapy was performed within 12 weeks before the first dose of study drug.
- •Subjects who have received other systemic anti-tumor therapy within 4 weeks before the first dose of study drug.
- •Subjects who received or are scheduled to receive live attenuated vaccine within 4 weeks.
- •Received systemic steroids equivalent to >10mg/d prednisone within 2 weeks before the first dose of study drug, except inhaled steroids.
- •Subjects who have undergone or are expected to undergo major surgery, or have severe unhealed wounds, etc. prior to the first dose of study drug.
- •Ever received any treatments targeting Claudin18.
- •Subject who have a history of allergy to any component in the DR
- •Subject with uncontrolled intracranial metastases.
- •Uncontrollable pleural effusion, pericardial effusion and ascites effusion existed before enrollment.
- •hepatitis B virus (HBV), hepatitis C virus (HCV), HIV or syphilis infection.
- •Diseases or associated risks that are judged by the investigator to be inappropriate for enrollment, such as poorly controlled diabetes,etc.
- •Subjects with interstitial lung disease requiring treatment such as oral or intravenous corticosteroids.
- •Subjects with previous or concomitant malignancies, with the following exceptions: non- melanoma skin carcinoma in situ, superficial bladder cancer, etc.
- •Clinically significant cardiovascular and cerebrovascular diseases within 6 months before the first dose of study drug, such as New York Heart Association (NYHA) class III or IV congestive heart failure, etc.
- •Female patients who are breastfeeding.
- •The investigator assesses that the subject is unable or unwilling to comply with the requirements of the research protocol.
- •Participated in other clinical studies within the past 4 Weeks.
研究组 & 干预措施
DR30303
DR30303 injection treatment. This phase 1 trial will include two stages, a dose escalation stage and an expansion stage.
干预措施: DR30303 (Drug)
结局指标
主要结局
Part 1：Incidence of dose limiting toxicities (DLTs)
时间窗: up to 21 days following first dose
Part 1：Number, severity and duration of treatment-emergent adverse events (TEAEs) according to the National Cancer Institute Common Terminology Criteria for Adverse Events (NCI-CTCAE) version 5.0
时间窗: up to 28 days following last dose
Part 1：Maximum Tolerated Dose (MTD) and/or Biological effective dose (BED) based on safety, tolerability, PK profile and preliminary efficacy data
时间窗: from date of last dose until the date of will receive DR30303 for 1 year or last documented progression，whichever occurs first
Part 2: Recommended Phase 2 Dose (RP2D) based on safety, tolerability, PK profile, and preliminary efficacy data
时间窗: from date of first dose start until the date of first documented progression，or the date of death from any cause, or the date of will receive DR30303 for 1 year whichever came first
Part 2: Number, severity and duration of treatment-emergent adverse events (TEAEs) according to the National Cancer Institute Common Terminology Criteria for Adverse Events (NCI-CTCAE) version 5.0
时间窗: up to 28 days following last dose
次要结局
- Objective response rate (ORR) per Response Evaluation Criteria in Solid Tumors (RECIST 1.1)(from date of first dose start until the date of first documented progression，or the date of death from any cause, or the date of will receive DR30303 for 1 year whichever came first)
- Disease control rate (DCR) per Response Evaluation Criteria in Solid Tumors (RECIST 1.1)(from date of first dose start until the date of first documented progression，or the date of death from any cause, or the date of will receive DR30303 for 1 year whichever came first)
- PK of DR30303: Time of the maximum concentration (tmax)(up to 28 days following last dose)
- Overall survival (OS) per RECIST v1.1(from date of first dose start until the date of first documented progression or death from any cause，or the date of will receive DR30303 for 1 year whichever came first)
- Duration of response (DOR) per Response Evaluation Criteria in Solid Tumors (RECIST 1.1)(from date of first dose start until the date of first documented progression，or the date of death from any cause, or the date of will receive DR30303 for 1 year whichever came first)
- PK of DR30303: Area Under the concentration-time Curve from time zero to infinity (AUC0-inf)(up to 28 days following last dose)
- PK of DR30303: Terminal elimination half-life (t1/2)(up to 28 days following last dose)
- Immunogenicity by measurement of Incidence of anti-drug antibodies (ADA)(up to 28 days following last dose)
- Clinical Benefit Rate(from date of first dose start until the date of first documented progression，or the date of death from any cause, or the date of will receive DR30303 for 1 year whichever came first)
- Duration of disease control (DDC) per RECIST v1.1(from date of first dose start until the date of first documented progression，or the date of death from any cause, or the date of will receive DR30303 for 1 year whichever came first)
- Pharmacokinetic (PK) of DR30303: Maximum serum concentration (Cmax)(up to 28 days following last dose)
- Progression free survival (PFS) per RECIST v1.1(from date of first dose start until the date of first documented progression，or the date of death from any cause, or the date of will receive DR30303 for 1 year whichever came first)
- 6-month and 12-month survival rates(from date of first dose start until the date of first documented progression , 6 months，12 months whichever came first)
- PK of DR30303: Area Under the concentration-time Curve from time zero to the last quantifiable concentration (AUC0-last)(up to 28 days following last dose)